Education
About Us
Working with TipRanks
Follow Us
Agios Pharmaceuticals (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$30.23
-$0.03(-0.09%)
At close: 4:00 PM EST
$30.23
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)815.86K
Market Cap
$1.71B
Enterprise Value$1.66B
Total Cash (Recent Filing)$854.42M
Total Debt (Recent Filing)$40.21M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Apr 30, 2026EPS Estimate
-1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding58,592,170
10 Day Avg. Volume741,480
30 Day Avg. Volume815,857
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue30.76
Enterprise Value/Gross Profit34.85
Enterprise Value/Ebitda-3.79
Forecast
1Y Price Target
$38.57Price Target Upside27.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.52
Revenue Forecast (FY)$89.69M
Bulls Say, Bears Say
Bulls Say
Early Physician UptakeInitial prescriptions and REMS certifications from both academic centers and community hematologists signal early clinical acceptance and potential for steady adoption across core treatment settings.
Pipeline Clinical CatalystsForthcoming clinical data readouts for pipeline candidates such as tebapivat and AG-236 present potential upside if positive results expand the company’s therapeutic footprint.
Regulatory Approval And LabelFDA approval of Aqvesme with a broad label for both transfusion-dependent and non-transfusion-dependent thalassemia establishes access to a wider patient population and supports a sizable commercial opportunity.
Bears Say
Launch Pace UncertaintyREMS dynamics combined with typical payer hurdles create the risk of a gradual launch trajectory, which could limit how quickly commercial revenue scales even if clinical demand is strong.
Payer And Authorization HurdlesPrior authorization and certification requirements can delay prescription fulfillment and postpone revenue recognition, weakening near-term sales momentum.
REMS Safety And Monitoring BurdenThe REMS program with intensive liver monitoring and a black box warning introduces additional safety oversight that could deter some initiations and add monitoring costs.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.71B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Feb 12, 2026. The company reported -$1.86 earnings per share for the quarter, beating the consensus estimate of -$1.954 by $0.094.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.79.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 58,592,170 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.86 in its last earnings report, beating expectations of -$1.954. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.57 (27.59% Upside)
$38.57 (27.59% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 15.9%
Last 30 Days ▼ 15.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.96%
12-Months-Change
Fundamentals
Return on Equity
-30.20%
Trailing 12-Months
Asset Growth
-22.00%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and pipeline momentum: notable Q4 revenue growth (86% YoY), Afesmi U.S. approval and an encouraging early launch (44 prescriptions in five weeks), a robust near-term catalyst calendar, and a healthy balance sheet (~$1.2B). Offsetting risks include near-term revenue timing delays (10–12 week conversion from script to treatment), anticipated sequential U.S. revenue decline into early 2026 due to ordering and inventory dynamics, sizeable R&D/SG&A spend without a specific profitability timetable, and regulatory uncertainty around the sickle cell approval pathway. Overall, the positives (approval, growth, cash runway, and multiple upcoming data readouts) outweigh the operational and timing headwinds, supporting an optimistic outlook.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$38.57
▲(27.59% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
Currently, No data available
---